Monthly Olanzapine Injection

What is WELTRUZA and how does it work?

Teva announced that the U.S. Food and Drug Administration approved WELTRUZA (olanzapine) extended-release injectable suspension for subcutaneous use. The company describes it as the first once-monthly subcutaneous olanzapine product. Olanzapine is an atypical antipsychotic that affects dopamine and serotonin signaling in the brain; these signaling systems are involved in symptoms such as hallucinations and delusions.

A long-acting formulation releases medicine over time, so treatment is administered at scheduled intervals rather than taken as a daily tablet. This may suit some adults who and their clinicians choose a long-acting option, but it does not remove the need for ongoing follow-up. The prescribing information and a clinician’s assessment determine who can use the product and how treatment should begin.

Who might consider a monthly olanzapine injection?

Schizophrenia care is individualized and can include antipsychotic medication, psychosocial support, and regular monitoring. A monthly injection may reduce the number of medication-taking occasions a person must manage, but treatment decisions should account for prior response, preferences, other health conditions, and the practicalities of attending appointments. A long-acting medicine is not automatically more effective or suitable for every patient.

Olanzapine can cause weight gain and metabolic changes, including higher blood glucose and lipid levels. It may also cause sleepiness, dizziness, or other adverse effects. Patients and clinicians should review the product’s current FDA-approved prescribing information, discuss monitoring, and seek medical advice before changing or stopping an existing treatment.

What should patients ask before starting treatment?

Before starting, ask the prescriber how the injection fits with any current antipsychotic treatment, what to expect at the first appointment, and how often follow-up is needed. Confirm the approved dose and administration schedule with the healthcare team; these details should come from the official prescribing information, not from general news coverage.

Discuss personal risk factors for weight or blood-sugar changes, other medicines, pregnancy plans, and any past reactions to olanzapine. Seek urgent care for severe or rapidly worsening symptoms, and contact the treating team promptly about troubling side effects. Do not stop or alter antipsychotic treatment without discussing a plan with a clinician.